XV
Xvivo Perfusion AB (publ)
XVIPF · OTC
$21.80 +0.00% (+$0.00)
1M -14.44%
Market Cap 6.86B kr
P/E Ratio 77.72x
Div. Yield -
ROE 5.37%
Bulios Fair Price
$12.67
41.9% downside
Current Price
$21.8
Undervalued Fair Value Overvalued
According to Bulios Fair Price, XVIPF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
5/9Valuation
4 /100
Expensive P/E 77.72x
EV/EBITDA 37.33x
P/S 7.70x
Growth
83 /100
Growing EPS growth 8.87%
Rev. growth 24.95%
Book val. growth 13.81%
Profitability
76 /100
Strong Gross margin 66.41%
Net margin 9.91%
Op. margin 12.23%
Quality
77 /100
Excellent ROIC 30.36%
ROE 5.37%
ROA 34.03%
Debt
100 /100
Low Debt/Equity 0.06x
Current ratio 3.86x
Int. coverage 36.09x
Stability
35 /100
Moderate Beta 1.46x
Rev. volatility 24.59%
EPS volatility 244.38%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about XVIPF
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Christoffer Rosenblad
Employees
210
Headquarters
Mölndal
Upcoming events
22 OCT
Earnings
Upcoming earnings report